A Study of IBI3032 in Healthy Participants
Recruiting
Phase 1
Interventional Study
Healthy
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 32 (estimated)
- Sponsor
- Fortvita Biologics (USA)Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a randomized, double-blind, placebo-controlled Phase I clinical study evaluating the safety, tolerability, and PK of a single dose of IBI3032 in healthy participants. This is a single ascending dose (SAD) study. Approximately 32 healthy participants are expected to be enrolled in this study.
The screening period is 4 weeks. Eligible participants will be divided into 4 cohorts. Each cohort…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Healthy male or females, as determined by medical history
* Have safety laboratory results within normal reference ranges
Exclusion Criteria:
* Have known allergies toIBI3032， glucagon-like peptide-1 (GLP-1) analogs, related compounds
* Abnormal electrocardiogram (ECG) at sc…
Contacts